Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06011798 · ClinicalTrials.gov registry record · Phase 2
Assess the Efficacy and Safety of Repeat Intravitreal Injections of Foselutoclax (UBX1325) in Patients With DME (ASPIRE)
A Phase 2 study, sponsored by Unity Biotechnology.
- Completed
- Registry status
- Phase 2
- Development phase
- 52
- Enrollment target
NCT06011798 is a Phase 2 study that has completed, run by Unity Biotechnology. The registered enrollment target is 52 participants.
The verdict
NCT06011798, a Phase 2 study, has completed, sponsored by Unity Biotechnology.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 52 participants
- Enrollment target
Study Summary
The goal of this clinical trial is to assess the efficacy and safety of multiple doses of foselutoclax (UBX1325) in patients with Diabetic Macular Edema. The main questions the study aims to answer are: * Assess the efficacy of foselutoclax compared to aflibercept * Assess the safety and tolerability of foselutoclax
Interventions
- DRUG Aflibercept
- DRUG foselutoclax
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 52 participants |
| Start Date | 2023-08-23 |
| Est. Completion | 2025-04-08 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06011798
The ClinicalTrials.gov registry entry for NCT06011798 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 52 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Unity Biotechnology, which has 9 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Aflibercept is the first listed.
NCT06011798 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT06011798 about?
NCT06011798 is a clinical study titled "Assess the Efficacy and Safety of Repeat Intravitreal Injections of Foselutoclax (UBX1325) in Patients With DME (ASPIRE)". The goal of this clinical trial is to assess the efficacy and safety of multiple doses of foselutoclax (UBX1325) in patients with Diabetic Macular Edema. The main questions the study aims to answer are: * Assess the efficacy of foselutoclax compared to aflibercept * Assess the safety and tolerabili...
What is the current status of trial NCT06011798?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 52 participants. The study started on 2023-08-23. Estimated completion is 2025-04-08.
What interventions are being tested in trial NCT06011798?
The interventions under investigation include: Aflibercept (DRUG), foselutoclax (DRUG).
Who is sponsoring clinical trial NCT06011798?
This trial is sponsored by Unity Biotechnology, which has 9 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.